Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia

被引:102
作者
Daskalopoulou, SS
Tzovaras, V
Mikhailidis, DP
Elisaf, M [1 ]
机构
[1] Univ Ioannina, Sch Med, Dept Internal Med, GR-45110 Ioannina, Greece
[2] Univ London, Royal Free & Univ Coll Med Sch, Royal Free Hosp, Dept Clin Biochem, London, England
关键词
uric acid; urate; uricosuric; fenofibrate; losartan; NSAID; diuretic; atorvastatin;
D O I
10.2174/138161205774913309
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Beyond allopurinol and the well-established uricosuric drugs, several other agents can decrease serum uric acid (SUA) levels, such as losartan, fenofibrate and some non-steroidal anti-inflammatory drugs (NSAIDs). Some of these drugs increase renal urate excretion. Hyperuricaemia and gout are common problems (at least 1% of Western men are affected by gout). Raised SUA levels increase the incidence of acute gout and renal calculi. Hyperuricaemia may also predict an increased risk of vascular events. Therefore, lowering SUA levels is of clinical relevance. In this review we consider the effect on SUA levels of drugs that are prescribed for indications other than treating hyperuricaemia. These drugs may obviate the need for specific treatment (e.g. allopurinol) aimed at lowering SUA levels. Furthermore, because hyperuricaemic patients may already be on several drugs (e.g. due to associated dyslipidaemia, hypertension and/or arthritis) compliance may be improved by avoiding additional medication. The potential for adverse effects associated with polypharmacy would also be decreased.
引用
收藏
页码:4161 / 4175
页数:15
相关论文
共 285 条
[1]   The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide [J].
Achimastos, A ;
Liberopoulos, E ;
Nikas, S ;
Bairaktari, E ;
Miltiadous, G ;
Tsimihodimos, V ;
Elisaf, M .
CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (02) :59-63
[2]   Beneficial changes in serum apo A-1 and its ratio to apo B and HDL in stable hyperlipidaemic subjects after Ramadan fasting in Kuwait [J].
Akanji, AO ;
Mojiminiyi, OA ;
Abdella, N .
EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2000, 54 (06) :508-513
[3]   Uric acid: role in cardiovascular disease and effects of losartan [J].
Alderman, M ;
Aiyer, KJV .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (03) :369-379
[4]   Uric acid and cardiovascular risk [J].
Alderman, MH .
CURRENT OPINION IN PHARMACOLOGY, 2002, 2 (02) :126-130
[5]   Serum uric acid and cardiovascular events in successfully treated hypertensive patients [J].
Alderman, MH ;
Cohen, H ;
Madhavan, S ;
Kivlighn, S .
HYPERTENSION, 1999, 34 (01) :144-150
[6]   Aminoglycoside-induced reversible tubular dysfunction [J].
Alexandridis, G ;
Liberopoulos, E ;
Elisaf, M .
PHARMACOLOGY, 2003, 67 (03) :118-120
[7]   DIURETIC ACTIVITY, SAFETY AND PHARMACOKINETICS OF TORASEMIDE DURING CHRONIC TREATMENT IN NORMAL SUBJECTS [J].
AMBROES, Y ;
RONFLETTE, I ;
DODION, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 :1-7
[8]  
[Anonymous], 2003, MED SCI MONIT
[9]   Fulminant hepatic failure associated with benzbromarone treatment: A case report [J].
Arai, M ;
Yokosuka, O ;
Fujiwara, K ;
Kojima, H ;
Kanda, T ;
Hirasawa, H ;
Saisho, H .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (05) :625-626
[10]   Statins and renal function in patients with diabetes mellitus [J].
Athyros, VG ;
Papageorgiou, AA ;
Elisaf, M ;
Mikhailidis, DP .
CURRENT MEDICAL RESEARCH AND OPINION, 2003, 19 (07) :615-617